EAN 2024 | Why are newer treatments not used first line in myasthenia gravis?

Francesco Sacca, MD, PhD, University of Naples Federico II, Naples, Italy, outlines the reasons why complement inhibitors and FcRn inhibitors are not used as first line treatments for myasthenia gravis (MG). A primary reason is cost — they cost more than 100,000 EUR per patient per year. They are also new — while there is no evidence of severe adverse events, they have not existed long enough for there to be long term studies on safety. It is therefore preferred for patients with good responses to low doses of steroids and immunosuppressants to remain on these treatments. This interview took place at the European Academy of Neurology (EAN) Annual Meeting 2024 in Helsinki, Finland.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.